NASDAQ:SNY Sanofi (SNY) Stock Price, News & Analysis $48.43 +0.20 (+0.41%) Closing price 04:00 PM EasternExtended Trading$48.37 -0.06 (-0.12%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sanofi Stock (NASDAQ:SNY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sanofi alerts:Sign Up Key Stats Today's Range$47.52▼$48.4650-Day Range$39.12▼$48.4352-Week Range$39.07▼$52.68Volume2.44 million shsAverage Volume4.94 million shsMarket Capitalization$117.42 billionP/E Ratio23.98Dividend Yield3.63%Price Target$53.00Consensus RatingHold Company Overview Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973. It later expanded through mergers, including the 2004 combination of Sanofi-Synthélabo and Aventis, and adopted the Sanofi name in 2011. The company is headquartered in Paris.AI Generated. May Contain Errors. Read More Sanofi Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreSNY MarketRank™: 3.873543657545 of 5 starsSanofi scored higher than 77% of companies evaluated by MarketBeat, and ranked 118th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingSanofi has received a consensus rating of Hold. The company's average rating score is 2.48, and is based on 1 strong buy rating, 8 buy ratings, 12 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Sanofi is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageSanofi has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sanofi's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.69% Earnings GrowthEarnings for Sanofi are expected to grow by 7.69% in the coming year, from $5.07 to $5.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sanofi is 23.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Sanofi is 23.98, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.39.Price to Earnings Growth RatioSanofi has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioSanofi has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.51% of the float of Sanofi has been sold short.Short Interest Ratio / Days to CoverSanofi has a short interest ratio ("days to cover") of 2.85, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sanofi has recently increased by 5.85%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend LeadershipSanofi is a leading dividend payer. It pays a dividend yield of 3.66%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthSanofi does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Sanofi is 87.13%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Sanofi will have a dividend payout ratio of 32.23% next year. This indicates that Sanofi will be able to sustain or increase its dividend.Read more about Sanofi's dividend. News and Social Media2.9 / 5News Sentiment0.59 News SentimentSanofi has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sanofi this week, compared to 6 articles on an average week.Search Interest12 people have searched for SNY on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat Follows12 people have added Sanofi to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sanofi insiders have not sold or bought any company stock.Percentage Held by Insiders1.00% of the stock of Sanofi is held by insiders.Percentage Held by Institutions14.03% of the stock of Sanofi is held by institutions.Read more about Sanofi's insider trading history. Receive SNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNY Stock News HeadlinesSanofi (NASDAQ:SNY) Upgraded at Wall Street ZenNovember 10 at 2:31 AM | americanbankingnews.comSanofi 2026 Q3 - Results - Earnings Call PresentationNovember 3, 2026 | seekingalpha.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 11 at 1:00 AM | Paradigm Press (Ad)Sanofi (SNY) Q3 2026 Earnings Call TranscriptNovember 2, 2026 | finance.yahoo.comSanofi (NASDAQ:SNY) Sees Strong Trading Volume Following Earnings BeatNovember 1, 2026 | americanbankingnews.comRegeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks UpOctober 30, 2026 | 247wallst.comSanofi Q3 Profit Climbs On Dupixent Growth; Raises FY26 Guidance; Stock UpOctober 30, 2026 | rttnews.comSanofi Tops Q3 2026 Expectations as Dupixent Sales Reach $6.36 BillionOctober 30, 2026 | 247wallst.comSee More Headlines SNY Stock Analysis - Frequently Asked Questions How have SNY shares performed this year? Sanofi's stock was trading at $48.46 at the start of the year. Since then, SNY shares have decreased by 0.1% and is now trading at $48.43. How were Sanofi's earnings last quarter? Sanofi (NASDAQ:SNY) issued its quarterly earnings data on Friday, October, 30th. The company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.56 by $0.48. The company's quarterly revenue was up 16.2% compared to the same quarter last year. Read the conference call transcript. Does Sanofi have any subsidiaries? The following companies are subsidiaries of Sanofi: Kiadis Pharma, Principia BioPharma, Synthorx, Ablynx, Bioverativ, Aventis S.A., Ablynx N.V., and others. Who are Sanofi's major shareholders? Sanofi's top institutional investors include Fisher Asset Management LLC (0.40%), Mondrian Investment Partners LTD (0.23%), Boston Partners (0.16%) and Equity Investment Corp (0.11%). View institutional ownership trends. How do I buy shares of Sanofi? Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sanofi own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sanofi investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Advanced Micro Devices (AMD), Merck & Co., Inc. (MRK) and Gilead Sciences (GILD). Company Calendar Last Earnings10/30/2026Today11/11/2026Jefferies Global Healthcare Conference11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, SNY's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SNY CIK1121404 Webwww.sanofi.com Phone(315) 377-4000Fax33-1-53-77-43-03Employees74,846Year Founded1994Price Target and Rating Average Price Target for Sanofi$53.00 High Price Target$57.00 Low Price Target$49.00 Potential Upside/Downside+9.4%Consensus RatingHold Rating Score (0-4)2.48 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)$2.02 Trailing P/E Ratio23.98 Forward P/E Ratio8.87 P/E Growth1.32Net Income$8.84 billion Net Margins8.70% Pretax Margin12.87% Return on Equity15.16% Return on Assets8.48% Debt Debt-to-Equity Ratio0.20 Current Ratio1.12 Quick Ratio0.27 Sales & Book Value Annual Sales$49.35 billion Price / Sales2.38 Cash Flow$7.09 per share Price / Cash Flow6.83 Book Value$34.77 per share Price / Book1.39Miscellaneous Outstanding Shares2,424,430,000Free Float2,400,181,000Market Cap$117.42 billion OptionableOptionable Beta0.31 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:SNY) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.